Could a yeast vaccine stop Cancer's return?
NCT ID NCT05952934
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a vaccine made from candida (a type of yeast) to see if it can reduce the risk of head and neck cancer coming back. About 100 adults who have finished cancer treatment and are currently cancer-free will receive either the vaccine or a placebo over two years. The goal is to compare recurrence rates between the two groups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Candin (candida therapeutic vaccine)
What this could lead to
If it works, this could offer a new way to lower the chance of head and neck cancer coming back after standard treatment.
What could go wrong
This is an early phase II trial with only 100 people, so results may not apply to everyone. The vaccine may not reduce recurrence and could cause side effects like injection site reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Highlands Oncology Group, PA
RECRUITINGFayetteville, Arkansas, 72762, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Highlands Oncology Group, PA
RECRUITINGRogers, Arkansas, 75758, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Highlands Oncology Group, PA
RECRUITINGSpringdale, Arkansas, 72762, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Perlmutter Cancer Center at NYU Langone Health
RECRUITINGMineola, New York, 11501, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Perlmutter Cancer Center at NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Arkansas for Medical Sciences
RECRUITINGLittle Rock, Arkansas, 72205, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••